Year: 2024
Type: article
Abstract: Results: The patients included: melanoma (n¼14), NSCLC (n¼10), endometrial cancer (n¼4), breast cancer (n¼3), GI cancer (n¼ 1), head/neck cancer (n¼1), RCC (n¼1) and urothelial cancer (n¼1), treated with ICI alone (n¼21) or with chemotherapy (n¼14).At 12 months of follow-up, 47.1% had experienced an irAE with 80.8% grade 1-2 and 19.2% grade 3-4.Neutrophil counts (P¼0.02) and the neutrophil/lymphocyte ratio (P¼0.05) were higher at baseline in patients experiencing an irAE.Furthermore increases in the percent of total CD4+ (P¼0.03),Th1 (P¼0.04), and Tfh1 (P¼0.01)cells, coupled with decreases in Th17 (P¼0.003) and Tfh17 (P¼0.03) cells in the blood at 8-11 weeks on treatment were significantly associated with an irAE.Conclusions: These results suggest that changes in the relative balance of neutrophils and specific CD4+ T cell subpopulations were linked with an irAE.Our ongoing studies will further investigate changes in cytokine and gene expression profiles to deepen our understanding of these associations.This study marks a first step toward identifying biomarkers that anticipate the onset of an irAE and consequently reduce the need for immunosuppressive treatment that could compromise the efficacy of ICIs.Clinical trial identification: NCT05429866.
Source: Immuno-Oncology Technology
Institutions: Institute of Oncology Research, Istituto Oncologico Veneto, Azienda Ospedaliera Universitaria Integrata Verona, Azienda Ospedale - Università Padova, University of Padua, Veneto Institute of Molecular Medicine, University of Verona, Ospedale Regionale di Bellinzona e Valli, Istituto Oncologico della Svizzera Italiana
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,170
OpenAlex ID: W4405374539